Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 INSIGHTS FROM PRIMARIES
  • 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
• 2.3 MARKET GROWTH FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
• 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023)
• 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023
• 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029
• 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing burden of chronic diseases
    • 5.2.1.2 Advancements in drug delivery technologies
    • 5.2.1.3 Higher patient compliance and preference for oral route
    • 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of drug development
    • 5.2.2.2 Contraindication of oral proteins & peptides
    • 5.2.2.3 Stringent regulatory approval process
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
    • 5.2.3.2 Growing demand for personalized medicine
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Hurdles in formulation and stability
    • 5.2.4.2 Availability of alternative therapies
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 ROLE OF RAW MATERIAL VENDORS
  • 5.3.2 ROLE OF PRODUCT PROVIDERS
  • 5.3.3 ROLE OF END USERS
  • 5.3.4 ROLE OF REGULATORY AUTHORITIES
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 THREAT OF NEW ENTRANTS
  • 5.6.2 THREAT OF SUBSTITUTES
  • 5.6.3 BARGAINING POWER OF SUPPLIERS
  • 5.6.4 BARGAINING POWER OF BUYERS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.7.1 KEY STAKEHOLDERS
  • 5.7.2 BUYING CRITERIA
• 5.8 PRICING ANALYSIS
  • 5.8.1 PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS
  • 5.8.2 PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY SCENARIO
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Transient permeation enhancer
    • 5.11.1.2 Gastrointestinal permeation enhancement technology
    • 5.11.1.3 Oral sCT (OSTORA) technology
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Peptelligence
    • 5.11.2.2 ThioMatrix
    • 5.11.2.3 Transferrin-based recombinant fusion protein
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Oramed and Orasome
    • 5.11.3.2 Q-sphera
    • 5.11.3.3 Nanoinclusion
    • 5.11.3.4 Oleotec and Soctec
• 5.12 PIPELINE ANALYSIS
• 5.13 PATENT ANALYSIS
  • 5.13.1 METHODOLOGY
  • 5.13.2 INNOVATION AND PATENT APPLICATIONS
  • 5.13.3 TOP APPLICANTS
• 5.14 KEY CONFERENCES & EVENTS, 2024-2025
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET

6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE

• 6.1 INTRODUCTION
• 6.2 SEMAGLUTIDE
  • 6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
• 6.3 CALCITONIN
  • 6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
• 6.4 LINACLOTIDE
  • 6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
• 6.5 TROFINETIDE
  • 6.5.1 FDA APPROVAL TO SUPPORT GROWTH
• 6.6 VOCLOSPORIN
  • 6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
• 6.7 PLECANATIDE
  • 6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
• 6.8 OTHER MOLECULES

7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS

• 7.1 INTRODUCTION
• 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
  • 7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
• 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
  • 7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
• 7.4 GUANYLATE CYCLASE-C AGONISTS
  • 7.4.1 RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET
• 7.5 GLYCINE-PROLINE-GLUTAMATE
  • 7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
• 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
  • 7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
• 7.7 OTHER DRUG CLASSES

8 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 DIABETES
  • 8.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
• 8.3 CNS DISORDERS
  • 8.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 8.4 GASTROENTEROLOGY
  • 8.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
• 8.5 GENETIC DISORDERS
  • 8.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
• 8.6 NEPHROLOGY
  • 8.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
• 8.7 OBESITY & OVERWEIGHT
  • 8.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
• 8.8 OTHER THERAPEUTIC AREAS

9 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION

• 9.1 INTRODUCTION
• 9.2 TABLETS
  • 9.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
• 9.3 CAPSULES
  • 9.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
• 9.4 ORAL SOLUTIONS
  • 9.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH

10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOME CARE SETTINGS
  • 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
• 10.4 HOSPITALS & SPECIALTY CLINICS
  • 10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH

11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 US to hold large share of North American and global markets
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to hold largest share of European market
  • 11.3.3 UK
    • 11.3.3.1 Strong focus on advancement of life sciences to support market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing R&D expenditure to drive market
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing prevalence of diabetes to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to hold largest market share in Latin America
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing diabetes and obesity cases to support market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to propel market
    • 11.6.2.3 Rest of GCC countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
  • 11.7.2 AFRICA: MACROECONOMIC OUTLOOK

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES
• 12.3 REVENUE SHARE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
• 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
  • 12.6.1 STARS
  • 12.6.2 EMERGING LEADERS
  • 12.6.3 PERVASIVE PLAYERS
  • 12.6.4 PARTICIPANTS
  • 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.6.5.1 Company Footprint
    • 12.6.5.2 Molecule footprint
    • 12.6.5.3 Formulation footprint
    • 12.6.5.4 Therapeutic area footprint
    • 12.6.5.5 Region footprint
• 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.7.1 PROGRESSIVE COMPANIES
  • 12.7.2 RESPONSIVE COMPANIES
  • 12.7.3 DYNAMIC COMPANIES
  • 12.7.4 STARTING BLOCKS
  • 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 12.7.5.1 Detailed list of key startups/SMEs
    • 12.7.5.2 Competitive benchmarking of key startups/SMEs
• 12.8 VALUATION & FINANCIAL METRICS
  • 12.8.1 FINANCIAL METRICS
  • 12.8.2 COMPANY VALUATION
• 12.9 BRAND/PRODUCT COMPARISON
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 INTRODUCTION
• 13.2 KEY PLAYERS
  • 13.2.1 NOVO NORDISK A/S
    • 13.2.1.1 Business overview
    • 13.2.1.2 Products offered
    • 13.2.1.3 Recent developments
      • 13.2.1.3.1 Product launches & approvals
      • 13.2.1.3.2 Expansions
      • 13.2.1.3.3 Other developments
    • 13.2.1.4 MnM view
      • 13.2.1.4.1 Right to win
      • 13.2.1.4.2 Strategic choices
      • 13.2.1.4.3 Weaknesses & competitive threats
  • 13.2.2 ABBVIE INC.
    • 13.2.2.1 Business overview
    • 13.2.2.2 Products offered
    • 13.2.2.3 Recent developments
      • 13.2.2.3.1 Product approvals
    • 13.2.2.4 MnM view
      • 13.2.2.4.1 Right to win
      • 13.2.2.4.2 Strategic choices
      • 13.2.2.4.3 Weaknesses & competitive threats
  • 13.2.3 PFIZER INC.
    • 13.2.3.1 Business overview
    • 13.2.3.2 Product pipeline
    • 13.2.3.3 Recent developments
      • 13.2.3.3.1 Product approvals
      • 13.2.3.3.2 Deals
      • 13.2.3.3.3 Other developments
    • 13.2.3.4 MnM view
      • 13.2.3.4.1 Right to win
      • 13.2.3.4.2 Strategic choices
      • 13.2.3.4.3 Weaknesses & competitive threats
  • 13.2.4 BAUSCH HEALTH COMPANIES INC.
    • 13.2.4.1 Business overview
    • 13.2.4.2 Products offered
    • 13.2.4.3 Recent developments
      • 13.2.4.3.1 Product approvals
  • 13.2.5 CHIESI FARMACEUTICI S.P.A.
    • 13.2.5.1 Business overview
    • 13.2.5.2 Products offered
    • 13.2.5.3 Recent developments
      • 13.2.5.3.1 Deals
  • 13.2.6 ACADIA PHARMACEUTICALS INC.
    • 13.2.6.1 Business overview
    • 13.2.6.2 Products offered
    • 13.2.6.3 Recent developments
      • 13.2.6.3.1 Product approvals
  • 13.2.7 AURINIA PHARMACEUTICALS INC.
    • 13.2.7.1 Business overview
    • 13.2.7.2 Products offered
    • 13.2.7.3 Recent developments
      • 13.2.7.3.1 Product approvals
  • 13.2.8 MERCK & CO., INC.
    • 13.2.8.1 Business overview
    • 13.2.8.2 Product pipeline
    • 13.2.8.3 Recent developments
      • 13.2.8.3.1 Other developments
  • 13.2.9 JOHNSON & JOHNSON SERVICES, INC.
    • 13.2.9.1 Business overview
    • 13.2.9.2 Product pipeline
    • 13.2.9.3 Recent developments
      • 13.2.9.3.1 Other developments
  • 13.2.10 SWK HOLDINGS
    • 13.2.10.1 Business overview
    • 13.2.10.2 Product pipeline
    • 13.2.10.3 Recent developments
      • 13.2.10.3.1 Other developments
  • 13.2.11 R-PHARM JSC
    • 13.2.11.1 Business overview
    • 13.2.11.2 Products in pipeline
  • 13.2.12 ENTERA BIO LTD.
    • 13.2.12.1 Business overview
    • 13.2.12.2 Product pipeline
    • 13.2.12.3 Recent developments
      • 13.2.12.3.1 Deals
      • 13.2.12.3.2 Other developments
  • 13.2.13 PROXIMA CONCEPTS
    • 13.2.13.1 Business overview
    • 13.2.13.2 Products in pipeline
• 13.3 OTHER PLAYERS
  • 13.3.1 ASTRAZENECA PLC
  • 13.3.2 REGOR THERAPEUTICS GROUP
  • 13.3.3 TERNS PHARMACEUTICALS, INC.
  • 13.3.4 STRUCTURE THERAPEUTICS
  • 13.3.5 VIKING THERAPEUTICS
  • 13.3.6 PROTAGONIST THERAPEUTICS INC.
  • 13.3.7 RANI THERAPEUTICS
  • 13.3.8 CARMOT THERAPEUTICS, INC.
  • 13.3.9 ZEALAND PHARMA
  • 13.3.10 SCIWIND BIOSCIENCES CO., LTD.
  • 13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS
• TABLE 2 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS
• TABLE 3 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS
• TABLE 4 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS
• TABLE 5 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES
• TABLE 6 ORAL PROTEINS & PEPTIDES MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 7 BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER
• TABLE 8 PRICING ANALYSIS, BY PRODUCT, 2024
• TABLE 9 PRICING ANALYSIS, BY COUNTRY AND REGION (USD), 2024
• TABLE 10 REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET
• TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF AUGUST 2024)
• TABLE 16 ORAL PROTEINS & PEPTIDES MARKET: TOP 20 PATENT OWNERS, 2014-2024
• TABLE 17 INDICATIVE LIST OF PATENTS IN ORAL PROTEINS & PEPTIDES MARKET, 2022-2024
• TABLE 18 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
• TABLE 19 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 20 SEMAGLUTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 21 NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 22 EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 23 ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 24 LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 25 MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 26 GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 27 CALCITONIN MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 28 NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 29 EUROPE: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 30 ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 31 LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 32 MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 33 GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 34 LINACLOTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 35 NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 36 EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 37 ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 38 LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 39 MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 40 GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 41 TROFINETIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 42 NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 43 EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 44 ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 45 LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 46 MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 47 GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 48 VOCLOSPORIN MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 49 NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 50 EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 52 PLECANATIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 53 NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 54 EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 55 ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 56 LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 58 GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 59 OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 60 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 61 EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 62 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 63 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 64 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 65 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 67 GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 68 NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 69 EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 70 ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 71 LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 72 MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 73 GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 74 CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 75 NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 76 EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 77 ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 78 LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 79 MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 80 GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 81 GC-C AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 82 NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 83 EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 84 ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 85 LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 86 MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 87 GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 88 GPE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 89 NORTH AMERICA: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 90 EUROPE: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 91 ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 92 LATIN AMERICA: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 93 MIDDLE EAST: GPE MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 94 GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 95 CNI MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 96 NORTH AMERICA: CNI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 97 EUROPE: CNI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 98 ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 99 OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 100 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 101 EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 102 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 103 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 104 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 105 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 106 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 107 ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 108 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 109 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 110 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 111 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 112 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 113 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 114 ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 115 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 116 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 117 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 118 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 119 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 120 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 121 ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 122 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 123 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 124 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 125 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 126 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 127 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 128 ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 129 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 130 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 131 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 132 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 133 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 134 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 135 ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION, 2022-2029 (USD MILLION)
• TABLE 136 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 137 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 138 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 139 ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2022-2029 (USD MILLION)
• TABLE 140 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 141 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 142 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 143 ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 144 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 145 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 146 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 147 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 148 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 149 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 150 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 151 ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 152 NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 153 EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 154 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 155 LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 156 MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 157 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 158 ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 159 NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 160 EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 161 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 162 LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 163 MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 164 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 165 ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 166 NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 167 EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 168 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 169 LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 170 MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 171 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 172 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 173 ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 174 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 175 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 176 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 177 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 178 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 179 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 180 ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 181 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 182 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 183 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 184 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 185 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
• TABLE 186 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 187 ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 188 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 189 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 190 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 191 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 192 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
• TABLE 193 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 194 ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 195 NORTH AMERICA: MACROECONOMIC OUTLOOK
• TABLE 196 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 197 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 198 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 199 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 200 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 201 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 202 US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 203 US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 204 US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 205 US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 206 US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 207 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 208 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 209 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 210 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 211 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 212 EUROPE: MACROECONOMIC OUTLOOK
• TABLE 213 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 214 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 215 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 216 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 217 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 218 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 219 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 220 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 221 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 222 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 223 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 224 UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 225 UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 226 UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 227 UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 228 UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 229 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 230 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 231 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 232 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 233 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 234 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 235 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 236 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 237 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 238 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 239 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 240 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 241 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 242 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 243 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 244 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 245 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 246 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 247 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 248 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 249 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 250 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 251 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 252 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 253 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 254 ASIA PACIFIC: MACROECONOMIC OUTLOOK
• TABLE 255 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 256 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 257 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 258 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 259 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 260 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 261 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 262 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 263 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 264 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 265 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 266 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 267 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 268 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 269 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 270 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 271 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 272 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 273 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 274 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 275 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 276 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 277 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 278 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 279 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 280 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 281 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 282 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 283 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 284 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 285 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 286 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 287 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 288 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 289 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 290 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 291 LATIN AMERICA: MACROECONOMIC OUTLOOK
• TABLE 292 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 293 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 294 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 295 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 296 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 297 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 298 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 299 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 300 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 301 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 302 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 303 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 304 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 305 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 306 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 307 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 308 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 309 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 310 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 311 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 312 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 313 MIDDLE EAST: MACROECONOMIC OUTLOOK
• TABLE 314 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 315 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 316 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 317 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 318 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 319 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 320 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 321 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 322 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 323 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 324 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 325 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 326 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 327 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 328 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 329 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 330 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 331 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 332 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 333 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 334 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 335 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 336 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 337 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 338 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 339 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 340 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 341 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 342 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 343 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 344 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 345 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 346 AFRICA: MACROECONOMIC OUTLOOK
• TABLE 347 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
• TABLE 348 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION)
• TABLE 349 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 350 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2022-2029 (USD MILLION)
• TABLE 351 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 352 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
• TABLE 353 ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION
• TABLE 354 ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS)
• TABLE 355 ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS)
• TABLE 356 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (KEY PLAYERS)
• TABLE 357 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
• TABLE 358 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS)
• TABLE 359 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
• TABLE 360 ORAL PROTEINS & PEPTIDES MARKET: KEY STARTUPS/SMES
• TABLE 361 ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 362 ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 363 ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 364 ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS, JANUARY 2021- AUGUST 2024
• TABLE 365 ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS, JANUARY 2021- AUGUST 2024
• TABLE 366 NOVO NORDISK: COMPANY OVERVIEW
• TABLE 367 NOVO NORDISK: PRODUCTS OFFERED
• TABLE 368 NOVO NORDISK: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 369 NOVO NORDISK: EXPANSIONS, JANUARY 2021- AUGUST 2024
• TABLE 370 NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021- AUGUST 2024
• TABLE 371 ABBVIE: COMPANY OVERVIEW
• TABLE 372 ABBVIE: PRODUCTS OFFERED
• TABLE 373 ABBVIE: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 374 PFIZER: COMPANY OVERVIEW
• TABLE 375 PFIZER: PRODUCT PIPELINE
• TABLE 376 PFIZER: PRODUCT APPROVALS, JANUARY 2021-AUGUST 2024
• TABLE 377 PFIZER: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 378 PFIZER: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
• TABLE 379 BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW
• TABLE 380 BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED
• TABLE 381 BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 382 CHIESI FARMACEUTICI: COMPANY OVERVIEW
• TABLE 383 CHIESI FARMACEUTICI: PRODUCTS OFFERED
• TABLE 384 CHIESI FARMACEUTICI: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 385 ACADIA PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 386 ACADIA PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 387 ACADIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 388 AURINIA PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 389 AURINIA PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 390 AURINIA PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021- AUGUST 2024
• TABLE 391 MERCK & CO.: COMPANY OVERVIEW
• TABLE 392 MERCK & CO.: PRODUCT PIPELINE
• TABLE 393 MERCK & CO.: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
• TABLE 394 JOHNSON & JOHNSON SERVICES: COMPANY OVERVIEW
• TABLE 395 JOHNSON & JOHNSON SERVICES: PRODUCT PIPELINE
• TABLE 396 JOHNSON & JOHNSON SERVICES: OTHER DEVELOPMENTS, JANUARY 2021- AUGUST 2024
• TABLE 397 SWK HOLDINGS: COMPANY OVERVIEW
• TABLE 398 SWK HOLDINGS: PRODUCT PIPELINE
• TABLE 399 SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
• TABLE 400 R-PHARM JSC: COMPANY OVERVIEW
• TABLE 401 R-PHARM JSC: PRODUCTS IN PIPELINE
• TABLE 402 ENTERA BIO: COMPANY OVERVIEW
• TABLE 403 ENTERA BIO: PRODUCT PIPELINE
• TABLE 404 ENTERA BIO: DEALS, JANUARY 2021-AUGUST 2024
• TABLE 405 ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
• TABLE 406 PROXIMA CONCEPTS: COMPANY OVERVIEW
• TABLE 407 PROXIMA CONCEPTS: PRODUCTS IN PIPELINE

List of Figures

• FIGURE 1 RESEARCH DESIGN
• FIGURE 2 BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS
• FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
• FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
• FIGURE 5 MARKET VALIDATION FROM PRIMARY EXPERTS
• FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
• FIGURE 7 CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2024-2029
• FIGURE 8 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET
• FIGURE 9 DATA TRIANGULATION METHODOLOGY
• FIGURE 10 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION)
• FIGURE 11 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS, 2024 VS. 2029 (USD MILLION)
• FIGURE 12 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET
• FIGURE 16 INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS TO DRIVE MARKET GROWTH
• FIGURE 17 TABLETS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
• FIGURE 18 DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• FIGURE 19 HOME CARE SETTINGS TO DOMINATE MARKET TILL 2029
• FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 21 ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 22 ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS
• FIGURE 23 ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS
• FIGURE 24 ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 25 ORAL PROTEINS & PEPTIDES MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 26 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF ORAL PROTEINS & PEPTIDES
• FIGURE 27 KEY BUYING CRITERIA FOR END USERS
• FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 29 TOTAL NUMBER OF PATENTS GRANTED, 2014-2024
• FIGURE 30 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
• FIGURE 31 ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO
• FIGURE 32 NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
• FIGURE 33 EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
• FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET, 2021-2023 (USD MILLION)
• FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES (2023)
• FIGURE 36 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 37 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
• FIGURE 38 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
• FIGURE 39 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
• FIGURE 40 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 41 EV/EBITDA OF KEY VENDORS
• FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 43 ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 44 NOVO NORDISK: COMPANY SNAPSHOT
• FIGURE 45 ABBVIE: COMPANY SNAPSHOT
• FIGURE 46 PFIZER: COMPANY SNAPSHOT
• FIGURE 47 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT
• FIGURE 48 CHIESI FARMACEUTICI: COMPANY SNAPSHOT
• FIGURE 49 ACADIA PHARMACEUTICALS: COMPANY SNAPSHOT
• FIGURE 50 AURINIA PHARMACEUTICALS: COMPANY SNAPSHOT
• FIGURE 51 MERCK & CO.: COMPANY SNAPSHOT
• FIGURE 52 JOHNSON & JOHNSON SERVICES: COMPANY SNAPSHOT
• FIGURE 53 SWK Holdings: Company Snapshot